Literature DB >> 7835377

The economic and social impact of migraine.

W F Stewart1, R B Lipton.   

Abstract

Migraine is an episodic disorder which is often disabling both during and between attacks. While pain intensity is the most important symptom to individual sufferers, headache-related disability is the major determinant of the economic impact of illness. Because migraine is underdiagnosed and under-treated, cost-effective healthcare interventions could serve to reduce the burden of illness on individual sufferers and society. Measures which assess both pain intensity and disability might serve to capture the essential elements of migraine and provide the basis for effective healthcare interventions.

Entities:  

Mesh:

Year:  1994        PMID: 7835377     DOI: 10.1159/000119527

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  9 in total

1.  The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis.

Authors:  R C Dodel; M Singer; R Köhne-Volland; T Szucs; B Rathay; E Scholz; W H Oertel
Journal:  Pharmacoeconomics       Date:  1998-09       Impact factor: 4.981

2.  A multinational investigation of the impact of subcutaneous sumatriptan. I: Design, methods and clinical findings.

Authors:  J Heywood; J Bouchard; P Cortelli; C Dahlöf; J P Jansen; S Pham; J Hirsch; C E Edwards; J Adams; P Berto; B Brueggenjuergen; A L Nyth; P Lindsay; K L Price
Journal:  Pharmacoeconomics       Date:  1997       Impact factor: 4.981

3.  Economic Evaluation of Treatments for Migraine: An Assessment of the Generalizability Following a Systematic Review.

Authors:  Matteo Ruggeri; Carlo Drago; Francesco Rosiello; Valentina Orlando; Costanza Santori
Journal:  Pharmacoeconomics       Date:  2020-05       Impact factor: 4.981

4.  Effect of preventive (beta blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: randomised controlled trial.

Authors:  Kenneth A Holroyd; Constance K Cottrell; Francis J O'Donnell; Gary E Cordingley; Jana B Drew; Bruce W Carlson; Lina Himawan
Journal:  BMJ       Date:  2010-09-29

5.  Acupuncture for chronic headache in primary care: large, pragmatic, randomised trial.

Authors:  Andrew J Vickers; Rebecca W Rees; Catherine E Zollman; Rob McCarney; Claire M Smith; Nadia Ellis; Peter Fisher; Robbert Van Haselen
Journal:  BMJ       Date:  2004-03-15

6.  Acupuncture for acute migraine attacks in adults: a systematic review protocol.

Authors:  Ruosang Du; Yang Wang; Xiaoxu Liu; Zhishun Liu
Journal:  BMJ Open       Date:  2015-04-13       Impact factor: 2.692

7.  Evaluating the prophylaxis and long-term effectiveness of acupuncture for migraine without aura: study protocol for a randomized controlled trial.

Authors:  Jiao Chen; Ling Zhao; Hui Zheng; Ying Li; Mingxiao Yang; Xiaorong Chang; Biao Gong; Yinlan Huang; Yanqin Liu; Fanrong Liang
Journal:  Trials       Date:  2013-10-30       Impact factor: 2.279

8.  Headache in epilepsy: A prospective observational study.

Authors:  Mark A Whealy; Anna Myburgh; Tanya J Bredesen; Jeffrey W Britton
Journal:  Epilepsia Open       Date:  2019-10-21

9.  Reduction in the severity and duration of headache following fremanezumab treatment in patients with episodic and chronic migraine.

Authors:  Messoud Ashina; Joshua M Cohen; Sanjay K Gandhi; Evelyn Du
Journal:  Headache       Date:  2021-06-11       Impact factor: 5.887

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.